Search Results
You are looking at 1 - 3 of 3 items for
- Author: Pasqualino Malandrino x
- Refine by access: All content x
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Giuseppe Fanciulli in
Google Scholar
PubMed
Search for other papers by Pasqualino Malandrino in
Google Scholar
PubMed
Search for other papers by Valeria Ramundo in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by on behalf of NIKE Group in
Google Scholar
PubMed
Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for therapeutic response are under intensive investigation, aiming at a tailored patient management and more appropriate resource utilization. This review summarizes the available data on the tissue, circulating and imaging markers that are potentially predictive of rapalog efficacy in NETs.
Search for other papers by Fiorenza Gianì in
Google Scholar
PubMed
Search for other papers by Giuseppe Pandini in
Google Scholar
PubMed
Search for other papers by Nunzio Massimo Scalisi in
Google Scholar
PubMed
Search for other papers by Paolo Vigneri in
Google Scholar
PubMed
Search for other papers by Carmine Fazzari in
Google Scholar
PubMed
Search for other papers by Pasqualino Malandrino in
Google Scholar
PubMed
Search for other papers by Marco Russo in
Google Scholar
PubMed
Search for other papers by Romilda Masucci in
Google Scholar
PubMed
Search for other papers by Antonino Belfiore in
Google Scholar
PubMed
Search for other papers by Gwabriella Pellegriti in
Google Scholar
PubMed
IC Crystallography Institute, National Research Council, CNR, Catania, Italy
Search for other papers by Riccardo Vigneri in
Google Scholar
PubMed
Thyroid cancer incidence is increased in volcanic areas where environment pollution biocontaminates residents. Tungsten (W) is the most increased heavy metal in drinking water of Mount Etna volcanic area where it exceeds the normal range in the urine of 27% inhabitants. The possible connection between increased tungsten and thyroid cancer has never been studied. We investigated in vitro the effect tungsten on both human thyrocytes in primary culture, thyrospheres (aggregates of stem/precursor thyroid cells) and thyrocytes differentiated from tungsten-exposed thyrospheres. Chronic exposure to low-dose (nanomolar range, as in the urines of volcanic area residents) soluble tungsten had major biological effects on thyroid stem/precursor cells, promoting growth with a biphasic (hormetic) dose-response and reducing apoptosis. No such effects were observed in mature thyrocytes. In addition, tungsten-exposed thyrospheres had abnormal expression of genes commonly altered also in thyroid cancer and increased activation of the DNA-repair proteins H2AX and 53BP1. Moreover, exposure to tungsten decreased thyrosphere differentiation, as indicated by the reduced expression of thyroid-specific genes in derived thyrocytes that also showed preneoplastic changes such as increased anchorage-independent growth, clonogenic growth and migration capacity. The mechanism of action of tungsten on thyroid stem/precursor cells is unclear but involves membrane G-proteins and activation of the ERK signaling pathway. These data indicate that chronic exposure to slightly increased tungsten, harmless for mature thyrocytes, importantly affects the biology of stem/precursor thyroid cells and of their progeny, inducing characteristics of preneoplastic transformation.
Search for other papers by Pasqualino Malandrino in
Google Scholar
PubMed
Search for other papers by Abir Al Ghuzlan in
Google Scholar
PubMed
Search for other papers by Marine Castaing in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Bernard Caillou in
Google Scholar
PubMed
Search for other papers by Jean-Paul Travagli in
Google Scholar
PubMed
Search for other papers by Dominique Elias in
Google Scholar
PubMed
Search for other papers by Thierry de Baere in
Google Scholar
PubMed
Search for other papers by Clarisse Dromain in
Google Scholar
PubMed
Search for other papers by Angelo Paci in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Eric Baudin in
Google Scholar
PubMed
To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line. We retrospectively studied prospectively collected parameters from 131 consecutive patients with metastatic ACC (44 with a tissue specimen available) treated at the Gustave Roussy Institute with mitotane- and platinum-based chemotherapy. Fifty-five patients with clinical, pathological, and morphological data available together with treatment characteristics including detailed follow-up were enrolled. Plasma mitotane levels and ERCC1 protein staining were analyzed. Response was analyzed according to RECIST criteria as well as overall survival (OS) from the start of cisplatinum-based chemotherapy. Parameters impacting on OS were evaluated by univariate analysis, and then analyzed by multivariate analysis. Using a landmark method, OS according to response to chemotherapy was analyzed. Objective response to combined mitotane- and cisplatinum-based chemotherapy was 27.3%. Median OS was 1 year. In the univariate analysis, resection of the primary, time since diagnosis, mitotane monotherapy as single first-line treatment, number of affected organs, plasma mitotane above 14 mg/l, and objective response were predictors of survival. In the multivariate analysis, mitotane level ≥14 mg/l and objective response to platinum-based chemotherapy were found to be independent predictors of survival (P=0.03 and <0.001). Our study suggests a prognostic role for mitotane therapy and objective response to platinum-based chemotherapy.
